Drug Trial News

RSS

Conference reviews recent evidence that links aspirin use with reduced risk of several cancers

Recent evidence linking aspirin use with a reduced risk of several cancers could change the risk benefits analysis in favour of wider use of aspirin, concluded a meeting organized by the Aspirin Foundation.

25 May 2011

New clinical research study to compare two medications for bipolar disorder

Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications -- quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.

25 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Radius Health, Inc. and 3M Drug Delivery Systems today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP analog, for the treatment of osteoporosis.

24 May 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

Santarus, Inc., a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.

23 May 2011

Phytoceuticals to present promising clinical data on 1 PRIMARY WOUND DRESSING at EWMA 2011

Phytoceuticals Ltd. will present promising clinical and scientific data on 1 PRIMARY WOUND DRESSING at the 2011 EWMA Conference on May 26, the largest European wound management conference.

23 May 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Oxford BioMedica, a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin for the treatment of Parkinson's disease were presented at the American Society of Gene & Cell Therapy 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011.

23 May 2011

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.

23 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

Drug Trial News

Conference reviews recent evidence that links aspirin use with reduced risk of several cancers

New clinical research study to compare two medications for bipolar disorder

Positive interim results from new bladder cancer therapy trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop

Phytoceuticals to present promising clinical data on 1 PRIMARY WOUND DRESSING at EWMA 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News